BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Vascular Closure Systems, Inc. Announces 30-Day Follow-Up Results for Phase I of the First in Human (FIH) Clinical Use, of the FastSeal® Bioabsorbable Vascular Access Closure System


6/29/2012 9:45:00 AM

PALO ALTO, Calif.--(BUSINESS WIRE)--Vascular Closure Systems, Inc.:

30-Day Follow-Up Results of the First in Human (FIH) Clinical Test Series of the FastSeal® Bioabsorbable Vascular Access Closure System – 100% Success Rate, Including Patients with Challenging Anatomy and Vessel Condition.

The company is pleased to announce that the 30-Day follow-up results for the Phase I FIH clinicals have been perfect, as confirmed by doppler and ultrasound evaluation. The evaluation confirmed normal vessel healing, with complete absorption of the FastSeal® sealing element. During the follow-up, no adverse events were observed - no hematoma, pseudoaneurysm or fistulas were present in any of the patients. All patients were asymptomatic and the comfort of the device was excellent, with no groin pain during the deployment, immediately after, at 7, and 30-days after the procedure.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES